MIDAS, HITAP and NUS hosted workshops on February 20, 2025, and March 28, 2025, for the Diagnostics Development Hub (DxD Hub), Agency for Science, Technology and Research (A*STAR), Ministry of Trade and Industry, Singapore. These workshops aimed to strengthen participants’ understanding of Health Technology Assessment (HTA) and early HTA, providing essential frameworks and methodologies for evaluating the clinical and economic value of medical innovations.
The session on February 20, 2025, led by Dr. Wang Yi from MIDAS, experts from HITAP, Dr. Yot Teerawattananon and Dr. Wanrudee Isaranuwatchai, and experts from NUS, Assoc Prof. Wee Hwee Lin and Prof. Alec Morton, introduced the theme “Introduction to Health Technology Assessment (HTA) and Early Health Technology Assessment (Early HTA).” The session aimed to enhance participants’ understanding of HTA and early HTA processes, emphasizing their role in guiding innovation during research and development to facilitate successful adoption into public healthcare systems. Additionally, it covered the fundamental skills required to conduct HTA and early HTA effectively with an overview of HTA agencies in different countries, regulatory frameworks governing HTA in Singapore and Thailand, and essential economic evaluation skills necessary for conducting HTA and early HTA effectively.
The March 28, 2025 session, led by Dr. Wang Yi, Dr. Teerawat Wiwatpanit, and Dr. Arpaporn Sutipatanasomboon from MIDAS, was a hands-on workshop focused on technical skills for economic evaluations. This second session centered on practical applications, using DxD Hub’s innovations and clinical trials as case studies. The MIDAS team developed specialized training packages on trial-based economic evaluation of an AI digital health technology and use-case scoping for early HTA of a precision medicine technology for hereditary disease screening in Asian populations.
